Cipla Nicotex Nicotine Transdermal Patch Step 1 21mg - WHO Approved Therapy for Quitting Smoking - 7 Patches

Key Features: - Nicotine transdermal patch for quitting smoking - WHO approved therapy - Step 1 with 21mg dosage - Contains 7 patches

For whom: - Smokers looking to quit - Individuals struggling with nicotine addiction - Those seeking a convenient and effective method to reduce cravings and withdrawal symptoms

Pros: - Easy to use and apply - Gradual nicotine reduction helps in managing cravings - Clinically proven to be effective in smoking cessation - WHO approved therapy ensures safety and efficacy

Cons: - May cause skin irritation for some users - Requires commitment and dedication to the quitting process - Not suitable for pregnant women or individuals with certain medical conditions

Factor	Weight	Contribution	Rationale	Sources
Spec/Feature Fit	25	20	Nicotine patch with WHO approval and suitable dosage for initial quitting phase.	The Hindu, Economic Times
Brand Strength	20	18	Cipla's strong reputation in pharmaceuticals and healthcare sector in India.	Business Standard, Livemint
Category Momentum	20	15	Growing demand for smoking cessation products in Indian market.	Mint, ET
Price Positioning	20	10	Competitively priced compared to similar products in the market.	Business Today, CNBC
Competition	10	8	Facing competition from other established nicotine replacement brands in India.	Financial Express, Hindu Business Line
Use-case Advantage	5	5	Convenient and discreet method for nicotine replacement therapy.	India Today
Final Market Score	100	76/100 (3.80/5)	Strong brand and feature fit position Cipla Nicotex well in the growing Indian smoking cessation market.

Factor	Rating (out of 5)	Notes
Social Media Buzz	0.0	—
Retail Presence	0.0	—
Price Appeal	0.0	—
Community Hype	0.0	—
Festive Sales	0.0	—
Performance in Climate	0.0	—